Filing Flows › Lenz Therapeutics (LENZ) › Q2 2026
Lenz Therapeutics (LENZ) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Lenz Therapeutics (LENZ) reported revenue of $5.5M for the second quarter 2026 (Q2 2026), +10% from a year earlier and +189% from the quarter before. Operating margin was -622.9%, net loss $31.9M (581.8% of revenue).
Lenz Therapeutics, Q2 2026: revenue $5.5M (+10% year over year), operating margin -622.9%, net loss $31.9M, operating cash flow −$38.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.5M | +189% | +10% |
| Operating profit | −$34.2M | — | — |
| Net earnings | −$31.9M | — | — |
| Operating cash flow | −$38.7M | — | — |
What changed
Revenue was $5.5M in Q2 2026, up 10% year over year and up 189% from the previous quarter. License revenue was the largest line at 68% of revenue. License revenue declined 25%.
Operating costs exceeded revenue by $34.2M, an operating margin of -622.9%. Total costs grew 81% against revenue growth of 10%. The fastest-growing cost line was SG&A (+208%). The quarter ended with a net loss of $31.9M, narrower than the previous quarter's $41.5M loss.
Operating cash flow was −$38.7M. Non-cash charges added back $110K of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $11.4M. Capital expenditures of $16K exceeded it, leaving free cash flow of −$38.7M.
Questions
What was Lenz Therapeutics' revenue in the second quarter 2026?
Lenz Therapeutics (LENZ) reported revenue of $5.5M for the second quarter 2026 (Q2 2026), +10% from a year earlier and +189% from the quarter before.
Was Lenz Therapeutics profitable in the second quarter 2026?
Operating loss was $34.2M (-622.9% of revenue) and net loss $31.9M.
Source: Lenz Therapeutics 10-Q on SEC EDGAR.